Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07071038 · ClinicalTrials.gov registry record · Phase 2

Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

A Phase 2 study of Breast Cancer and Early Stage Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center.

Recruiting
Registry status
Phase 2
Development phase
62
Enrollment target
1
Study location

NCT07071038 is a Phase 2 study of Breast Cancer and Early Stage Breast Cancer that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 62 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07071038, a Phase 2 study of Breast Cancer and Early Stage Breast Cancer, is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.

RECRUITING
Registry status
Phase 2
Development phase
62 participants
Enrollment target
1
Study location

Study Summary

Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor. An aromatase inhibitor is hormone therapy that lowers the chance of breast cancer coming back (recurring) after surgery by blocking an enzyme in fat tissue called aromatase; aromatase changes other hormones in the body to estrogen. Women who do not complete the standard 5-year treatment are at higher risk of their cancer coming back. The goal of this research is to prevent breast cancer from coming back after surgery by helping women to stay on treatment with aromatase inhibitors. Researchers believe the best path to help women to stay on treatment is to create a better way to manage (control) side effects.

Conditions Studied

Breast Cancer Early Stage Breast Cancer Adjuvant Treatment

Interventions

  • DRUG Switch
  • OTHER Guideline Directed Intervention (GDI)

Study Locations (1)

New Hampshire

  • Dartmouth Cancer Center - Lebanon

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2025-10-17
Est. Completion 2027-08-05
Phase Phase 2

Sponsor

Dartmouth-Hitchcock Medical Center

427 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07071038

The ClinicalTrials.gov registry entry for NCT07071038 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Switch is the first listed.

NCT07071038 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.

Frequently Asked Questions

What is clinical trial NCT07071038 about?

NCT07071038 is a clinical study titled "Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients". Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor. An aromatase inhibitor is hormone therapy that lowers the chance of breast cancer coming back (recurring) after surgery by blocking an enzyme in fat tissue called a...

What is the current status of trial NCT07071038?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2025-10-17. Estimated completion is 2027-08-05.

What conditions does trial NCT07071038 study?

This clinical trial studies the following conditions: Breast Cancer, Early Stage Breast Cancer, Adjuvant Treatment.

What interventions are being tested in trial NCT07071038?

The interventions under investigation include: Switch (DRUG), Guideline Directed Intervention (GDI) (OTHER).

Who is sponsoring clinical trial NCT07071038?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07071038 being conducted?

This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Early Stage Breast Cancer

All registered trials for this condition

New Hampshire

All trials with a study site in New Hampshire

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.